Clarity Pharmaceuticals Future Growth
Future criteria checks 0/6
Clarity Pharmaceuticals is forecast to grow earnings and revenue by 68.2% and 61.5% per annum respectively. EPS is expected to grow by 64% per annum. Return on equity is forecast to be 8.5% in 3 years.
Key information
68.2%
Earnings growth rate
64.0%
EPS growth rate
Pharmaceuticals earnings growth | 47.7% |
Revenue growth rate | 61.5% |
Future return on equity | 8.5% |
Analyst coverage | Low |
Last updated | 04 Nov 2024 |
Recent future growth updates
Recent updates
We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth
Sep 23Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth
Jan 03We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow
May 29Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth
Aug 24Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation
Jan 13Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2027 | 61 | -3 | -14 | -13 | 1 |
6/30/2026 | 28 | -3 | 11 | 12 | 2 |
6/30/2025 | N/A | -49 | -52 | -51 | 2 |
6/30/2024 | 12 | -42 | -44 | -43 | N/A |
3/31/2024 | 10 | -36 | -41 | -40 | N/A |
12/31/2023 | 9 | -31 | -38 | -38 | N/A |
9/30/2023 | 10 | -28 | -33 | -33 | N/A |
6/30/2023 | 10 | -25 | -28 | -27 | N/A |
3/31/2023 | 10 | -23 | -24 | -24 | N/A |
12/31/2022 | 9 | -21 | -21 | -21 | N/A |
9/30/2022 | 8 | -23 | -17 | -17 | N/A |
6/30/2022 | 6 | -24 | -14 | -13 | N/A |
3/31/2022 | 6 | -21 | -13 | -13 | N/A |
12/31/2021 | 5 | -19 | -12 | -12 | N/A |
9/30/2021 | 4 | -15 | -10 | -10 | N/A |
6/30/2021 | 3 | -10 | -8 | -8 | N/A |
3/31/2021 | 3 | -9 | -7 | -7 | N/A |
12/31/2020 | 3 | -9 | -7 | -7 | N/A |
9/30/2020 | 3 | -8 | -7 | -7 | N/A |
6/30/2020 | 3 | -7 | -7 | -7 | N/A |
6/30/2019 | 3 | -4 | -4 | -4 | N/A |
6/30/2018 | 2 | -2 | -2 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CU6 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CU6 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CU6 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CU6 is forecast to have no revenue next year.
High Growth Revenue: CU6 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CU6's Return on Equity is forecast to be low in 3 years time (8.5%).